NFKB1 and metabolic dysfunction-associated steatotic liver disease: USP4 [10], USP10 [11], and USP18 [12] have been demonstrated to alleviate NAFLD by suppressing insulin resistance and inflammation-related signals [specifically, the nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways].